Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis

Xin Li, PhD, Tarun K. Garg, PhD, Sarah K. Johnson, PhD, Susann Szmania, BS, Justin Stivers, BS, Wen Ling, MS, Sharmin Khan, MS, Priyangi Malaviarachchi, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2014) 124 (21): 2102.

https://doi.org/10.1182/blood.V124.21.2102.2102

Published: 2014

Journal Articles

Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis

Tarun K. Garg, PhD, Ricky D Edmondson, PhD, Shweta S. Chavan, PhD, Junaid Khan, PhD, Susann Szmania, BS, Justin Stivers, BS, Veronica Macleod, BS, Katie Stone, BS, Emily Woods, BS, Donald Johann, MD, MS, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2013) 122 (21): 3105.

https://doi.org/10.1182/blood.V122.21.3105.3105

Published: 2013

Journal Articles

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Susann Szmania, BS, Amy D Greenway, BS, Joshuah D Lingo, BS, Katie Stone, BS, Junaid Khan, PhD, Tarun K. Garg, PhD, Nathan M Petty, MS, Susan B. Panozzo, BS, Emily Woods, BS, Jessica Warden, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, Frits van Rhee, MD,PhD

Blood (2013) 122 (21): 5389.

https://doi.org/10.1182/blood.V122.21.5389.5389

Published: 2013

Journal Articles

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo .

Tarun K. Garg, PhD, Susann Szmania, BS, Paul Malbrough, BS, Charles Ekworomadu, MS, Katie Stone, BS, Amberly Moreno-Bost, BS, Emily Woods, BS, Jumei Shi, MD, PhD, Shmuel Yaccoby, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Dario Campana, MD, PhD, Frits van Rhee, MD, PhD

Blood (2009) 114 (22): 953.

https://doi.org/10.1182/blood.V114.22.953.953

Published: 2009

Journal Articles

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Jumei Shi, MD, PhD, Susann Szmania, BS, Guido Tricot, MD, PhD, Tarun K. Garg, PhD, Priyangi A Malaviarachchi, BS, Amberly Moreno-Bost, BS, Katie Stone, BS, Fenghuang Zhan, MD, PhD, Dario Campana, MD, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 2758.

https://doi.org/10.1182/blood.V112.11.2758.2758

Published: 2008

Journal Articles

Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab

Tarun K. Garg, PhD, Susann Szmania, BS, Jumei Shi, MD, PhD, Katie Stone, BS, Amberly Moreno-Bost, BS, Paul Malbrough, BS, Dario Campana, MD., PhD, Bart Barlogie, MD, PhD, Daniel Afar, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 3666.

https://doi.org/10.1182/blood.V112.11.3666.3666

Published: 2008

Journal Articles

Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103

Amberly Moreno-Bost, BS, Susann Szmania, BS, Katie Stone, BS, Jumei Shi, MD, PhD, Tarun K. Garg, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Hugh Grant Prentice, MD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 3674.

https://doi.org/10.1182/blood.V112.11.3674.3674

Published: 2008

Journal Articles

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Susann Szmania, BS, Balaji Balasa, PhD, Priyangi Malaviarachchi, BS, Fenguhuang Zhan, MD,PhD, Yongsheng Huang, MS, Aparna Draksharapu, MD, Vladimir Vexler, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD,PhD, Guido Tricot, MD,PhD, Daniel Afar, PhD, van Rhee Frits, MD,PhD

Blood (2006) 108 (11): 660.

https://doi.org/10.1182/blood.V108.11.660.660

Published: 2006

Journal Articles

Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.

Sacha Gnjatic, PhD, Susann Szmania, BS, Amberly Moreno, BS, M. Cottler-Fox, MD, John Shaughnessy, MD, Bart Barlogie, MD, PhD, Lloyd Old, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2005) 106 (11): 2197.

https://doi.org/10.1182/blood.V106.11.2197.2197

Published: 2005

Journal Articles

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

Jumei Shi, MD, PhD, Guido Tricot, MD, PhD, Susann Szmania, BS, Cristyn Camet, BS, Nancy Rosen, BS, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Dario Campana, MD, PhD, Frits van Rhee, MD, PhD

Blood (2005) 106 (11): 3392.

https://doi.org/10.1182/blood.V106.11.3392.3392

Published: 2005

Journal Articles

Soluble and Membrane Bound MICA in Myeloma Do Not Adversely Effect Regulation of Natural Killer Cell Function Via NKG2D..

Jumei Shi, MD, PhD, Susann Szmania, BS, Fenghuang Zhan, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2004) 104 (11): 2462.

https://doi.org/10.1182/blood.V104.11.2462.2462

Published: 2004

Journal Articles

A Novel Strategy for Combining Immunotherapy with High Dose Chemotherapy and Auto-Transplantation in High Risk Multiple Myeloma.

Susann Szmania, BS, Michele Cottler-Fox, MD, Nancy Rosen, BS, Sanjaya Viswamitra, MD, Amberly Moreno, BS, Mindy Pomtree, BS, Bart Barlogie, MD, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2004) 104 (11): 2920.

https://doi.org/10.1182/blood.V104.11.2920.2920

Published: 2004

NARROW

ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis

Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo .

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab

Recognition of Myeloma by MAGE-A3 Specific Cytotoxic T Lymphocytes Induced by Treatment with Azacitidine and MGCD0103

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

Soluble and Membrane Bound MICA in Myeloma Do Not Adversely Effect Regulation of Natural Killer Cell Function Via NKG2D..

A Novel Strategy for Combining Immunotherapy with High Dose Chemotherapy and Auto-Transplantation in High Risk Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only